Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

CD19-targeted CAR T cells BZ019

A preparation of T lymphocytes that have been genetically modified and transduced with a non-viral vector expressing a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) CD19 and containing, as of yet undisclosed co-stimulatory signaling domains, with potential immunostimulating and antineoplastic activities. Upon administration, CD19-targeted CAR T cells BZ019 recognize and bind to CD19-expressing tumor cells, thereby inducing selective toxicity in CD19-expressing tumor cells. CD19 antigen is a B-cell-specific cell surface antigen overexpressed in B-cell lineage malignancies.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:anti-CD19 CAR T cells BZ019
anti-CD19 CAR-T cells BZ019
Code name:BZ 019
BZ-019
BZ019
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search